Physician profile
Hannah J Dukeman
NPI 1326415845
$4,999.39
in general payments reported to CMS, 2019-2025
28 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 96% of Diabetes Educator providers received nationally (typical 2025 total: $111).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $1,316 · 2023: $1,351 · 2024: $1,016 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $739.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $471.93 | 2023-2025 | |
| Lilly USA, LLC | $402.35 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.34 | 2021-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $386.91 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $335.88 | 2022-2025 | Korlym |
| Radius Health, INC. | $321.10 | 2022-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $288.26 | 2022-2025 | |
| Insulet Corporation | $284.03 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $246.06 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $201.58 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $188.74 | 2021-2022 | |
| Amgen INC. | $122.96 | 2022-2025 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $100.72 | 2022-2023 | |
| Abbvie INC. | $77.73 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $62.49 | 2025 | Twiist |
| Abbott Laboratories | $54.81 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Medtronic, INC. | $50.66 | 2021-2023 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $40.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $39.14 | 2022-2025 | Strensiq |
| Horizon Therapeutics Plc | $36.63 | 2023 | Tepezza |
| Beta Bionics, INC. | $33.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $28.64 | 2022 | |
| Esperion Therapeutics, INC. | $23.53 | 2025 | Nexletol |
| Exact Sciences Corporation | $20.53 | 2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $17.77 | 2023 | Tremfya |
| Madrigal Pharmaceuticals | $16.62 | 2025 | Rezdiffra |
| Cequr Corporation | $9.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Dukeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.